Bone morphogenetic protein 2 receptor complex (BMP2R complex) (BMP2R complex)

The Bone morphogenetic protein 2 (BMP2) receptor complex is a heterotetrameric signaling assembly essential for mediating the effects of BMP2, a potent morphogen in the TGF-beta superfamily (Wikipedia, NIH). The complex typically consists of two type I receptors, such as BMPR1A (ALK3) or BMPR1B (ALK6), and two type II receptors, primarily BMPR2, though ACVR2A or ACVR2B can also participate (UniProt, PubMed). Upon binding of the BMP2 ligand, the constitutively active type II receptors phosphorylate the type I receptors, which then initiate downstream signaling through the canonical Smad1/5/8 pathway (GeneCards, NIH). This signaling cascade is critical for fundamental biological processes including bone and cartilage development, vascular homeostasis, and embryonic patterning (PubMed). Dysregulation of the complex, particularly through loss-of-function mutations in the BMPR2 component, is a primary driver of pulmonary arterial hypertension (PAH), where reduced signaling leads to uncontrolled vascular smooth muscle cell proliferation (NIH, StatPearls). In clinical practice, recombinant human BMP2 (rhBMP-2), such as Dibotermin alfa, is utilized as a bone graft substitute to promote osteogenesis in spinal fusions and fracture repairs (FDA, PubMed). However, therapeutic use of BMP2 is associated with significant safety concerns, including ectopic bone formation, severe inflammation, and life-threatening tissue swelling (NIH, FDA). Emerging therapies also target this complex to restore signaling balance in cardiovascular diseases or to inhibit its pro-oncogenic roles in certain cancers (PubMed).

Other names

BMP2 signaling complexBMPR2-BMPR1A complexBMPR2-BMPR1B complexBMP receptor complexBMP2-BMPR heterotetramer

Receptor complex agonism to induce osteogenesis; activation of BMPR2 signaling via FKBP12 inhibition to treat vascular remodeling; and ligand trapping to restore signaling balance in the BMP pathway.